scholarly article | Q13442814 |
P50 | author | Joseph Zohar | Q21104323 |
Stephen Stahl | Q24006564 | ||
Pierre U. Blier | Q46045677 | ||
Shigeto Yamawaki | Q92663506 | ||
Hans-Jürgen Möller | Q1577771 | ||
David Kupfer | Q5236159 | ||
Guy M. Goodwin | Q5622285 | ||
P2093 | author name string | Michael Spedding | |
David Nutt | |||
Hiroyuki Uchida | |||
P433 | issue | 12 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | neuroscience | Q207011 |
P304 | page(s) | 2318-2325 | |
P577 | publication date | 2015-09-07 | |
P1433 | published in | European Neuropsychopharmacology | Q15286536 |
P1476 | title | A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature | |
P478 | volume | 25 |
Q42399356 | A Neuroscience-Based Nomenclature (NbN) for Psychotropic Agents |
Q47750718 | A new nomenclature for classifying psychotropic drugs |
Q38665865 | Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. |
Q92476399 | Antipsychotic drugs: from 'major tranquilizers' to Neuroscience-based-Nomenclature |
Q92218063 | Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis |
Q37035659 | Classification of psychotropic drugs: Problems, solutions, and more problems |
Q48046839 | Current pharmacotherapy of depression - focused on multimodal/multifunctional antidepressants |
Q92850928 | Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis |
Q38797653 | Drugs, games, and devices for enhancing cognition: implications for work and society |
Q33716263 | Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews |
Q56962426 | Major depressive disorder |
Q28066691 | Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases |
Q42828114 | Neuroscience-based Nomenclature (NbN) for Clinical Psychopharmacology and Neuroscience |
Q48561791 | Neuroscience-based Nomenclature (NbN) for Journal of Psychopharmacology |
Q42379069 | Neuroscience-based Nomenclature (NbN): A call for action |
Q42131810 | Neuroscience-based nomenclature and medicolegal significance |
Q37730207 | New drugs in psychiatry: focus on new pharmacological targets |
Q42392349 | Prescribing according to diagnosis: how psychiatry is different |
Q64082982 | Prognosis and improved outcomes in major depression: a review |
Q48536218 | Progress on the Neuroscience-Based Nomenclature (NbN) for Psychotropic Medications |
Q39487850 | Risperidone increases the cortical silent period in drug-naive patients with first-episode schizophrenia: A transcranial magnetic stimulation study |
Q96028604 | Serotonin-2B receptor antagonism increases the activity of dopamine and glutamate neurons in the presence of selective serotonin reuptake inhibition |
Q34530580 | Suicide prevention strategies revisited: 10-year systematic review |
Q58586423 | Systemic neurotransmitter responses to clinically approved and experimental neuropsychiatric drugs |
Q47985236 | The in vitro actions of loxapine on dopaminergic and serotonergic receptors. Time to consider atypical classification of this antipsychotic drug? |
Q38957224 | Therapeutic Mechanisms of Lithium in Bipolar Disorder: Recent Advances and Current Understanding |
Q87708998 | Using neuroscience for naming psychotropic drugs |
Q90191620 | What do patients learn about psychotropic medications on the web? A natural language processing study |
Q57056580 | What's in a Name? Moving to Neuroscience-Based Nomenclature in Pediatric Psychopharmacology |
Search more.